logo-loader

Merus soars as Incyte backs it with US$200mln injection

Published: 09:10 21 Dec 2016 EST

picture of cells
Incyte will work on eleven of Merus's candidates

Nasdaq-listed drug developer Merus NV (NASDAQ:MRUS) added more than half to its market value as it agreed a tie-up with pharma research group Incyte (NASDAQ:INCY).

The deal will see Inctyte invest US$80mln in new Merus shares and pay an additional US$120mln for exclusive rights to eleven bispecific antibody research programs, including two pre-clinical immuno-oncology developments.

Netherlands-based Merus is keeping some rights to both its two clinical candidates and colorectal cancer hope MCLA-158.

Incyte will fund and develop the other eight with Merus earning potential milestone payments of US$350mln per candidate or US$2.8bn in total if all prove commercial.

“By virtue of a unique ability to simultaneously engage multiple protein targets, we believe bispecific antibodies have the potential to play an important role in the future of biotherapeutics,” said Reid Huber, Incyte’s chief scientific officer.

“This collaboration with Merus expands our large molecule discovery capabilities into an innovation-rich area of research.”

Pre-market trading saw Merus shares rise 50% from their overnight close of US$15.

Xeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for...

Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share news the company had a successful 2023, with a final tally of 164 million USD, which is at the upper end of their forecast. The company concluded the year with 72 million USD in cash, surpassing their initial projections...

9 hours, 27 minutes ago